Effects of bromodomain and extra-terminal inhibitor JQ1 and interleukin-6 on breast cancer cells

被引：0
|
作者：
Atefeh Sharifhoseini
Masoud Heshmati
Amin Soltani
Mahshad Entezam
Hedayatollah Shirzad
Morteza Sedehi
Babri A. Judd
Mohammad-Saeid Jami
Mahdi Ghatrehsamani
机构：
[1] Shahrekord University of Medical Sciences,Cellular and Molecular Research Center
[2] Shahrekord University of Medical Sciences,Department of Microbiology and Immunology
[3] Shahrekord University of Medical Sciences,Department of Epidemiology and Biostatistics, School of Health
[4] Immunology Science Editors,Department of Neurology, David Geffen School of Medicine
[5] University of California Los Angeles (UCLA),undefined
来源：
Molecular Biology Reports | 2023年 / 50卷
关键词：
Breast cancer; BET inhibitor; JQ1; IL-6; Breast cancer stem cell; CXCR4;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：8319 / 8328
页数：9
相关论文
共 44 条
  • [1] Effects of bromodomain and extra-terminal inhibitor JQ1 and interleukin-6 on breast cancer cells
    Sharifhoseini, Atefeh
    Heshmati, Masoud
    Soltani, Amin
    Entezam, Mahshad
    Shirzad, Hedayatollah
    Sedehi, Morteza
    Judd, Babri A.
    Jami, Mohammad-Saeid
    Ghatrehsamani, Mahdi
    MOLECULAR BIOLOGY REPORTS, 2023, 50 (10) : 8319 - 8328
  • [2] The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway
    Lei, Linping
    Xie, Xuqin
    He, Long
    Chen, Keling
    Lv, Zhaoying
    Zhou, Bin
    Li, Yuan
    Hu, Wenjun
    Zhou, Zongguang
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (02) : 362 - 376
  • [3] The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway
    Linping Lei
    Xuqin Xie
    Long He
    Keling Chen
    Zhaoying Lv
    Bin Zhou
    Yuan Li
    Wenjun Hu
    Zongguang Zhou
    Investigational New Drugs, 2021, 39 : 362 - 376
  • [4] Development and validation of an LC-MS/MS method to quantify the bromodomain and extra-terminal (BET) inhibitor JQ1 in mouse plasma and brain microdialysate: Application to cerebral microdialysis study
    Nair, Sreenath
    Davis, Abigail
    Campagne, Olivia
    Schuetz, John D.
    Stewart, Clinton F.
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2021, 204
  • [5] Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins
    Lai, Jiacheng
    Liu, Ziqiang
    Zhao, Yulei
    Ma, Chengyuan
    Huang, Haiyan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis
    Fu, Rong
    Zu, Shi-Jia
    Liu, Yan-Jun
    Li, Jia-Cheng
    Dang, Wen-Zhen
    Liao, Li-Ping
    Liu, Li-Ping
    Chen, Pan-Yu
    Huang, He-Ming
    Wu, Kang-Hui
    Zhou, Bing
    Pan, Qin
    Luo, Cheng
    Zhang, Yuan-Yuan
    Li, Guang-Ming
    BIOENGINEERED, 2022, 13 (04) : 10914 - 10930
  • [7] Novel inhibitors of bromodomain and extra-terminal domain trigger cell death in breast cancer cell lines
    Rahnasto-Rilla, Minna
    Puumalainen, Tatu
    Karttunen, Vilma
    Adla, Santosh Kumar
    Lahtela-Kakkonen, Maija
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 112
  • [8] Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells
    Gayle, Sylvia S.
    Sahni, Jennifer M.
    Webb, Bryan M.
    Weber-Bonk, Kristen L.
    Shively, Melyssa S.
    Spina, Raffaella
    Bar, Eli E.
    Summers, Mathew K.
    Keri, Ruth A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (03) : 875 - 886
  • [9] The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells
    Garcia, Patrick L.
    Miller, Aubrey L.
    Zeng, Ling
    van Waardenburg, Robert C. A. M.
    Yang, Eddy S.
    Yoon, Karina J.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line
    Wakabayashi, Hiroki
    Hamaguchi, Takahiko
    Nagao, Nobuto
    Kato, Sho
    Iino, Takahiro
    Nakamura, Tomoki
    Sudo, Akihiro
    BREAST CANCER, 2018, 25 (05) : 566 - 574
12345